BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
BIIB upcoming catalysts
Biogen: 1 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 7 readout(s) and 2 FDA event(s). Subscribe to BIIB (.ics).
Drugs: Litifilimab, Felzartamab
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-01 est. | P3 | Biogen BIIB | NCT06685757 A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) | Antibody-mediated Rejection | active not recruiting | 132 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-11-13 | FDA approval | approved | BIOGEN BIIB | ZURZUVAE | Approved 2026-11-13: ZURZUVAE (NDA217369 SUPPL4) |
| 2026-03-27 | FDA approval | approved | BIOGEN BIIB | SPINRAZA | Approved 2026-03-27: SPINRAZA (NDA209531 SUPPL16) |
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-20 est. | P2/P3 | Biogen BIIB | NCT05531565 A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus | active not recruiting | 450 |
| 2026-09-30 est. | P3 | Biogen BIIB | NCT04895241 A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythe | Lupus Erythematosus, Systemic | active not recruiting | 548 |
| 2026-09-27 est. | P3 | Biogen BIIB | NCT04961567 A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythe | Lupus Erythematosus, Systemic | active not recruiting | 562 |
| 2026-07-30 | P3 | Biogen BIIB | NCT04729907 A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who T | Muscular Atrophy, Spinal | completed | 115 |
| 2026-03-11 | P2 | Biogen BIIB | NCT05399888 A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to | Mild Cognitive Impairment Due to Alzheimer's Disease; Alzheimer's Disease Dementia | active not recruiting | 416 |
| 2026-03-09 | P2 | Biogen BIIB | NCT05348785 A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 | Parkinson Disease | completed | 650 |
| 2026-02-10 | P2 | Biogen BIIB | NCT05798520 A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing For | Relapsing Forms of Multiple Sclerosis | completed | 127 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.